

1 Probing the dissonance among the diagnostic outputs of multiple approaches used for
2 detection of Methicillin-resistant *Staphylococcus aureus* (MRSA)

3 Ujjwal Ranjan Dahiya,^a Arnab Sikidar,^a Priyanka Sharma,^b Chitra Rawat,^c Benu Dhawan,^b Arti
4 Kapil,^b Ravikrishnan Elangovan,^d Dinesh Kalyanasundaram^{a,e*}

5 ^a Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016

6 ^b Department of Microbiology, All India Institute of Medical Sciences, New Delhi 110029

7 ^c Council of Scientific and Industrial Research (CSIR)- Institute for Genomics and Integrative
8 Biology (IGIB), New Delhi 110020

9 ^d Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology
10 Delhi, New Delhi 110016

11 ^e Department of Biomedical Engineering, All India Institute of Medical Sciences, New Delhi
12 110029

13 * Corresponding author: dineshk@cbme.iitd.ac.in, dineshk.iitdelhi@gmail.com

14

15

16 This is to declare that the following authors do not have any conflict of interest:

17 Ujjwal Ranjan Dahiya: d.ujjwal.iitd@gmail.com

18 Arnab Sikidar: arnab.sikidar@gmail.com

19 Priyanka Sharma: priyankap2828@gmail.com

20 Chitra Rawat: chitrarawat11@gmail.com

21 Benu Dhawan: dhawanb@gmail.com

22 Arti Kapil: akapilmicro@gmail.com

23 Ravikrishnan Elangovan: elangovan@dbeb.iitd.ac.in

24 Dinesh Kalyanasundaram: dineshk.iitdelhi@gmail.com, dineshk@cbme.iitd.ac.in

25

26

27

28 **Abstract**

29 Methicillin resistant staphylococcus aureus (MRSA) is an extremely infectious hospital
30 acquired bacterial pathogen often found in post-surgical patients globally. Early detection of
31 such pathogens is a critical requirement to eliminate or reduce the incidence of anti-
32 microbial resistance as well as for effective management of the disease. Despite the
33 development of multiple biochemical, microbiological and nucleic acid amplifications
34 techniques (NAATs), conventional culture methods are widely used clinically owing to high
35 variability between the methods, technical skills and infrastructural needs. Further, multiple
36 reports suggest significant variation among diagnostic output for MRSA detection. This work
37 attempts to probe the discordance among the diagnostic output of three commonly used
38 methods, while trying to understand the underlying cause of variability. MRSA detection on
39 217 clinical pus isolates was carried out using three different methods namely, conventional
40 culture method, qPCR-based amplification and a modern LAMP based detection approach.
41 Also, to confirm the presence of MRSA and distinguish from coagulase-negative
42 staphylococci (CoNS), as well as to investigate the observed differences between qPCR and
43 LAMP outputs, melt curve analysis was performed on discordant samples. LAMP based
44 MRSA detection was found to be the optimum method. In summary, this study evaluates the
45 diagnostic efficiency of the different detection methods, while probing for possible
46 explanations for the observed differences.

47 **Keywords:** MRSA, LAMP, rapid diagnosis, cross-reactivity, melt curve analysis (MCA), qPCR,
48 Nucleic acid amplification techniques (NAATs)

49 **1. Introduction**

50 Globally, methicillin-resistant *Staphylococcus aureus* (MRSA) is associated with nosocomial
51 and community-acquired healthcare infections (1,2). Due to the extensive use of antibiotics
52 , an increasing number of antibiotic-resistant (ABR) bacterial strains such as MRSA is causing
53 enormous healthcare challenge to mankind (3,4). The pathogen is capable of producing a
54 diverse range of toxins and virulence factors, including toxic shock syndrome toxin (TSST)
55 (5). A higher mortality rate of about twenty-two percent is observed in MRSA infected
56 patients in comparison to five percent amongst non-MRSA patients (6–8). The resistance of
57 MRSA towards β -lactam based antibiotics including methicillin is caused by the presence of
58 inherent β -lactamase as well as the expression of *mecA* gene resulting in the production of
59 penicillin-binding proteins (PBP, PBP2, and PBP2a) that shows lower affinity to β -lactam
60 based antibiotics (9). Rapid identification and timely isolation of MRSA infected subjects are
61 crucial to avoid complications (10,11). Conventional methods for the detection of MRSA can
62 take up to 48 hours or more time due to time-consuming protocols including culture, colony
63 morphology, and anti-microbial susceptibility testing (12,13). Lately, health institutions are
64 giving high importance to rapid identification of bacterial isolates and screening of their
65 antimicrobial susceptibility, especially in positive blood culture isolates (14,15). This led to
66 deployment of multiple nucleic acid amplification techniques (NAAT) based approaches for
67 fast detection of MRSA and other pathogens (16). Many commercial assays based on
68 polymerase chain reaction (PCR) such as FluoroType® MRSA system (Hain-life science
69 GmbH, Nehren, Germany) have been developed. Although these assays are costly and
70 requires high technical skills (17,18).

71 Recently, the next step taken towards making MRSA detection fast and affordable with high
72 sensitivity and selectivity is the use of isothermal amplification approaches (19,20). The
73 various isothermal amplification methods are loop-mediated isothermal amplification
74 (LAMP), primer-generation rolling circle amplification (PG-RCA), recombinase polymerase
75 amplification (RPA), nucleic acid sequence-based amplification (NASBA), helicase-
76 dependent amplification (HDA), exponential amplification reaction (EXPAR), and whole
77 genome amplification (WGA). Among these, LAMP is a popular, well-studied, and
78 standardized nucleic acid amplification technique with high specificity and sensitivity (21).
79 LAMP utilizes polymerases such as Bst, capable of auto cycling strand-displacement
80 mediated amplification. A set of 4 or 6 specific primers along with dNTPs are necessary for
81 target sequence amplification (19). Amplification through LAMP method can be detected
82 through multiple methods viz. turbidimetric, fluorescence and pH changes in the reaction
83 mixture (22,23). Recent work from our group reported a portable system *SMOL* for the rapid
84 diagnosis of *Salmonella* Typhi and *Salmonella* Paratyphi A (14).

85 While working towards designing a LAMP-based assay for MRSA detection, a significant
86 discordance in diagnostic results was often observed in comparison to results of detection
87 through culture method and qPCR. Perplexed with the observation, we looked in the
88 literature and found multiple reports suggesting the differences in diagnostic results in
89 MRSA detection (24–27). In the present work, we aim to understand the degree of and
90 underlying factors behind such discordance. To achieve this, we compared the diagnostic
91 results in 217 mixed flora clinical samples, obtained by three different approaches viz.
92 LAMP-assay, qPCR method and culture method. The performance of these diagnostic
93 methods is comprehensively compared with each other in terms of sensitivity and

94 robustness. Available literature suggests presence of multiple pathogens, inhibitory protein
95 and coagulase-negative staphylococci (CoNS) contamination as some of the putative source
96 of error in MRSA detection (28). To assess the role of CoNS contamination, discordant results
97 between NAAT methods were subjected to melt curve analysis (MCA). Mass
98 spectrophotometry based detection of random samples was tried to substantiate the finding.
99 The study designed is comprehensively illustrated in Figure 1. The manuscript while
100 comprehensively assessing the effectiveness and robustness of these diagnostic methods,
101 also highlight and discuss the critical factors to be considered while developing a rapid MRSA
102 detection assay.

103

104 **2. Materials and methods**

105 2.1 Institute ethical approval and collection of clinical samples

106 The study was ethically approved by Institutional ethics committee (document number IEC-
107 569/02 dated 02.11.2018). Two hundred and seventeen clinical human pus samples were
108 collected from 203 patients with clinical symptoms of *Staphylococcus aureus* infection. In
109 fourteen patients, two samples were collected on different dates. The samples were collected
110 after taking consents from the volunteering patients. The pus samples were sent to the
111 department of microbiology from wards and out-patient department of All India Institute of
112 Medical Sciences, New Delhi.

113

114 2.2 Culture-based detection of MRSA

115 The detailed protocol for the conventional culture-based diagnostic approach for MRSA is
116 given in the supplementary section and involved culturing of the clinical samples on blood

117 and MacConkey Agar plates followed by biochemical tests. Clinical pus aspirates were plated
118 on blood Agar plate in carbon dioxide enriched atmosphere (5% CO₂ incubator) for
119 performing a β -hemolysis test. The presence of yellow to cream white colonies signified the
120 presence of *S. aureus* or *Streptococcus pyrogens*. For differentiating between two possible
121 pathogens, catalase tests were performed by mixing a small volume of inoculum from each
122 sample to a 3 % hydrogen peroxide solution. The release of bubbles confirms the presence
123 of MRSA in clinical isolates. Further, coagulase tests were performed by incubating the pus
124 samples with coagulase plasma (HIMEDIA®, India) for observation of blood clots on a glass
125 slide. Cefoxitin was used as a marker to detect methicillin resistance through antibiotic disc
126 diffusion tests and the results were analyzed by current CLSI guidelines.(29) To understand
127 the limit of detection, serial dilutions of MRSA cells spiked blood culture media were used
128 for standardizations for concentration range of 5 to 500 CFU/mL (supplementary section).
129 The conventional culture method takes about 72 hours. All the culture-based detection of
130 clinical pus samples were carried out at the Department of Microbiology of the associated
131 hospital.

132

133 2.3 Sample processing for NAAT based detection

134 Elution of samples in buffer was performed post 4 hours of incubation of the pus samples,
135 followed by lysis at 95 °C for 10 minutes in heated water bath. Pus sample supernatant thus
136 prepared was stored at 4 °C until required further. Supernatant from each clinical sample
137 was then used for setting up LAMP or qPCR reactions.

138

139 2.4 LAMP based detection of MRSA

140 LAMP reagents master mix were purchased from Optigene Private Limited, India, a
141 subsidiary of Ampligene, UK. The primers for *mecA* gene were custom designed by our group
142 and synthesized by Integrated DNA Technologies, USA, for LAMP experiments. LAMP based
143 nucleic acid amplification used in this study was based on 4 primers; forward outer primer
144 (F3), backward outer primer (B3), forward inner primer (FIP), and backward inner primer
145 (BIP). The FIP, BIP, F3, and B3 primers for the *mecA* gene were designed in PrimerExplorer®
146 version 5 (Table 1). BLAST® program was used for verification of primer specificity, prior
147 to experimentation. The LAMP method has been explained elsewhere in detail.(30) Before
148 setting up the reactions, solutions for primer mix and LAMP reagents mix were prepared to
149 enable faster, convenient and precise experimentation. For preparing primer mix, 20 µL
150 from 100 µM of FIP and BIP each, 5 µL from 100 µM of F3 and B3 each, and 30 µL of nuclease
151 free water were mixed. For the LAMP assay, 5 µL of primer mix, 10 µL of LAMP reagent mix,
152 5 µL of clinical sample lysate (template DNA) and 5 µL of nuclease free water was used to
153 setup a 25 µL reaction. All the samples were placed in a vial and sealed with parafilm before
154 the treatment at 65 °C for LAMP. Amplified LAMP reactions were tested after adding 2 µL of
155 1000X SYBR green in each tube, followed by visual detection of positive samples.

156

157 2.5 Cross-reactivity and specificity of LAMP assay

158 Several common pathogenic bacterial species such as *S. Havana*, *S. Paratyphi B*, *S.*
159 *Typhimurium*, *S. Typhi*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*,
160 *Enterococcus fecalis*, *Klebsiella pneumonia*, and *Shigella flexneri* at a concentration of 10⁶
161 CFU/mL were tested individually to evaluate the cross-reactivity of the primers. Similar

162 protocol of DNA isolation and LAMP amplifications were followed as described in the
163 preceding sections.

164

165 2.6 Quantitative *polymerase chain reaction* (qPCR)

166 KAPA SYBR master mix 2X was procured from Sigma Aldrich, USA, for qPCR-based
167 amplifications. All other reagents including buffers, broth, albumin, etc., were obtained from
168 Sigma-Aldrich, USA. qPCR reactions were carried out for validation of the results of clinical
169 samples. In addition to the above, known dilution of MRSA culture was used to generate the
170 standard curve between the *mecA* copy numbers (considering one copy of the gene per CFU)
171 and C_t values (obtained in the qPCR reactions). The outer primers F3 and B3 were used in
172 qPCR reactions to amplify the *mecA* gene. The standard curve of C_t vs. copy number was used
173 for estimating the copy number in the clinical pus samples. The lysate prepared (described
174 in the earlier sections) was used for the qPCR reactions. For both the clinical samples and for
175 the standard curve experiments, 7.5 μ L of KAPA SYBR 2X (Promega, USA) master mix, 2 μ L
176 of clinical sample lysate and 3 μ L of pre-mixed primers (10 μ M of F3 and B3 each) were used.
177 The reactions were carried out at 95°C for 30 s for initial denaturation followed by 40 cycles
178 of denaturation at 95°C for 10 s, and extension at 57°C for 30 s. The reactions were carried
179 out in real time qPCR machine LightCycler® 480 (Roche molecular systems Inc., USA).

180

181 2.7 Melt Curve Analysis for differentiation MRSA from CoNS

182 To further probe the differences observed between the diagnostic methods, melt curve
183 analysis (MCA) was performed. Primer sequences (Table 2) specific to the conservative
184 domains of *Staphylococcus* genus (16S), *S. aureus* (ITS), and *mecA* gene were used for the

185 assay.(31) For MCA assay, qPCR reactions were setup to check amplification of *16S*, *ITS*, and
186 *mecA* genes in the samples with discordant results between the two NAAT diagnostic
187 methods. The reactions were carried out in real-time qPCR machine CFX96® (BioRad
188 Technologies, USA). Samples in which all three gene sequences were amplified were
189 designated as MRSA, while samples with no amplification of *ITS* amplicon were designated
190 as CoNS positive.

191

192 2.8 Statistical analysis

193 The effectiveness and efficiency of the three diagnostic methods was estimated based on the
194 diagnostic outputs, by calculating the clinical sensitivity and negative predictive value
195 (NPV).(32) Power analysis was also performed on the results. For the sake of statistical
196 analysis, the samples with negative results in all three methods (absence of MRSA) were
197 taken as reference for estimating NPV and sensitivity.

198

199 3.0 Results

200 3.1 Cross-reactivity tests for the primers against other pathogens

201 The cross-reactivity was tested for the *mecA* primer sequences used for MRSA detection in
202 the study. LAMP was performed against nucleic acids of the following bacterial pathogens: *S.*
203 *Havana*, *S. Paratyphi B*, *S. Typhimurium*, *S. Typhi*, *Escherichia coli*, *Pseudomonas aeruginosa*,
204 *Acinetobacter baumannii*, *Enterococcus fecalis*, *Klebsiella pneumonia*, and *Shigella flexneri*.
205 Amplification in all samples was observed visually post addition of SYBR green. The primer
206 sequences were found to be specific and no amplification was observed with DNA of above-
207 mentioned organisms (Figure 2).

208 3.2 Diagnostic results for different approaches used for MRSA detection

209 MRSA detection on all 217 clinical samples was performed using three diagnostic
210 approaches as mentioned above and the diagnostic outputs were tabulated (Table 3).
211 Conventional culture-based MRSA detection on 217 clinical samples resulted in 30 positive
212 samples and 187 negatives (Figure 3). The isothermal amplification based LAMP method
213 was confirmed using visual detection after adding SYBR green dye and showed 104 positive
214 samples and 113 negatives.

215 qPCR based diagnosis as well as quantification of *mecA* copy number in clinical pus samples
216 was performed after preparing a standard curve between C_t vs *mecA* copy numbers
217 (supplementary section). qPCR based estimation of *mecA* copy number showed distinct
218 variation among the tested samples (supplementary section). Based on the standard curve,
219 a cut off value of C_t equal to 23.65 was used for distinguishing between the positive and
220 negative MRSA detection and further statistical analysis. qPCR based MRSA detection
221 resulted in 67 positive samples and 150 negative samples (Figure 2). On comparing the
222 diagnostic outputs, a total of 13 samples were found positive in all three methods while 95
223 samples were found negative across the methods (Figure 3). Sample-wise detailed results
224 for all three diagnostic approaches are included in the supplementary tables.

225

226 3.3 Statistical significance of different approaches

227 The sensitivity and Net predictive values (NPV) for MRSA detection in three methods were
228 estimated using statistical analysis based on the diagnostic outputs (Table 3). A total of 95
229 samples showed MRSA absence in all three approaches, and thus used as reference for
230 estimating sensitivity and negative predictive value (NPV). Culture based MRSA detection

231 showed a low sensitivity of 24.6% and NPV of 50.8%. LAMP based detection resulted in
232 85.2% sensitivity and 84.1% NPV. Sensitivity and NPV of 54.9% and 63.3% respectively was
233 observed in the case of qPCR-based MRSA estimation.

234

235 3.4 Estimating the discordance in diagnostic outputs

236 Observed MRSA detection result using three different methods showed significant
237 differences. To assess the degree of variability between the diagnostic outputs, we estimated
238 percentage discordance (non-concordant as a percentage of total) within the results. The
239 diagnostic outputs were categorized in 8 different group based on the results (Table 4a).
240 While considering results from all three methods together, a total of 108 samples (13
241 positive and 95 negative) showed concordant results, resulting in overall discordance of
242 50.2%. Next, we estimated the pairwise discordance between the approaches (Table 4b). In
243 pairwise comparison, highest discordance of 36.9% was observed between the results of
244 culture and LAMP methods. This was followed by an estimated discordance of 31.8%
245 between culture and qPCR results. Finally, between the two NAAT methods the estimated
246 discordance was found to be 31.8%.

247

248 3.5 Role of CoNS presence in the mixed culture (Melt curve Analysis)

249 Since both qPCR and LAMP based detection of MRSA in the study was based on *mecA* gene,
250 a significant discordance of 31.8% was poorly understood. To assess the role of CoNS
251 contamination in the observed discordance we performed MCA. The 69 discordant samples
252 between LAMP and qPCR methods were subjected to melt curve analysis (MCA) to find the
253 presence of CoNS in the samples. Samples were tested for specific amplification peaks of

254 *mecA* (79.5°C), ITS (86.5°C) and 16s rRNA (83.5°C) in melt curves. Amplification of ITS gene
255 along with the *mecA* gene and 16S rRNA gene confirms the presence of MRSA, while absence
256 of ITS peak in melt curve signified CoNS contamination. Melt curve analysis confirmed the
257 presence of CoNS in 17 out of the 69 tested samples, while rest were found to be CoNS
258 negative (Figure 4, Table 5).

259

260 **4. Discussion**

261 Infection by MRSA is a widely acknowledged public health challenge as one of the hospital-
262 acquired infections.(33) Low affinity penicillin-binding protein (PBP2), an altered protein
263 encoded by the *mecA* gene present in the chromosome *Staphylococcal* cassette chromosome
264 *mec* (SCCmec) is responsible for manifesting *methicillin* resistance in *S. aureus*.(34,35)
265 Treatment of MRSA is often challenging due to its association with multiple antimicrobial
266 resistances. Thus a rapid and accurate detection of MRSA infections can play a critical role in
267 effective treatment and management of patients (36).

268 In conventional culture-based detection of MRSA, samples showing bacterial growth on
269 primary plates are further processed for strain identification tests like coagulase and
270 catalase and then finally for anti-microbial susceptibility using disc diffusion assay. Culture
271 based detection of MRSA face inherent challenges including but not limited to longer
272 processing time and limited range of detection in low inoculum culture (12). Thus, the need
273 of a rapid and robust detection of MRSA has led to the development of multiple detection
274 approaches, majorly based on nucleic acid amplification of a specific gene in MRSA genome
275 (37,38). Despite the large number of efforts, a plethora of literature is available showcasing

276 the shortcomings of the available detection methods and the resultant variation among the
277 diagnostic methods (25,39).

278 MRSA detection can be performed on clinical isolates from several anatomical sites like
279 wound exudates (pus), nasal swabs, skin swabs, and blood samples with nasal swabs being
280 preferred by clinical test kits (40,41). However, the relevance of pus culture over other
281 anatomic samples, especially blood, is recently reported in the literature with new tests
282 being developed based on pus cultures (14,42,43).

283 The present study compared the diagnostic outputs of MRSA detection by three commonly
284 used approaches namely, culture-based method, *q*PCR, and loop-mediated isothermal
285 amplification. On comparing the diagnostic outputs of these methods, 95 samples were
286 found to be negative across the three methods and thus taken as negative controls for the
287 purpose of statistical analysis. A significant difference between the sensitivities of these
288 methods was seen with the culture-based method detecting 30 MRSA positive samples while
289 *q*PCR based assay detected 67 positive samples. Highest MRSA detection of 104 samples was
290 observed in LAMP-based assay. It would be imperative to mention that MRSA presence in 39
291 samples were exclusively identified by LAMP method (Table 4a).

292 Both overall and pairwise discordance were estimated and suggested considerable
293 differences in the diagnostics outputs(Figure 4a, 4b). Diagnostic results for NAATs methods
294 (*q*PCR and LAMP) showed significant discordance with culture method, and were able to
295 detect more number of MRSA bearing samples. The observed discordance between the
296 diagnostic outputs of culture and molecular method highlights the limitation of traditional
297 method given the time consuming protocols process and other variables including the slow
298 rate of growth of bacteria, reduced sensitivity due to presence of other pathogens, and pus

299 being a heterogeneous body fluid bearing high concentration of immune cells that hampered
300 the viability of the MRSA pathogen (44). Results of NAAT methods including *q*PCR and LAMP
301 were found to be more largely similar in comparison to culture based assay. Among the 69
302 samples found discordant between the NAATs methods, 53 were exclusively detected in
303 LAMP while 16 were detected MRSA positive in *q*PCR method. Since both LAMP and *q*PCR
304 assay are based on *mecA* gene amplification, observed discordance between the two is not
305 well-understood. Although, it can be explained to some extent considering high sensitivity
306 and robustness reported for LAMP based assays in multiple reports (32,45).

307 In addition to this, the presence of another pathogen CoNS possessing *mecA* gene and its
308 influence on NAAT methods based detection cannot be overlooked (31). The methicillin
309 resistance target gene *mecA* is often found in two organisms namely, CoNS and *S. aureus*,(28)
310 and hence merely detecting *mecA* is not sufficient to distinguish between MRSA and
311 methicillin resistant CoNS. Kahánková et al. employed a multi-locus PCR based approach to
312 amplify multiple DNA segments of both species simultaneously (46). However, the
313 performance of multi-locus PCR has yielded limited success as reported by other research
314 groups (47,48). Hence, melt curve analysis was performed in the 69 clinical pus samples
315 exhibiting discordant results to rule out the detection of false positives and differentiate
316 between MRSA and CoNS (Table 5). Seventeen samples were found to be CoNS positive,
317 while the rest 52 samples were found to be MRSA positive. Statistical analysis was again
318 performed for NAATs methods while considering the CoNS identified samples as negative
319 (Table 6). The results show that isothermal amplification (LAMP) based detection of MRSA
320 was found to be the robust approach among the three methods, with sensitivity of 85.7 and
321 NPV of 86.7% (Table 6).

322 LAMP is comparatively the latest detection assay amongst the three methods and could be
323 employed in hospital or commercial laboratory settings for rapid detection, given its low
324 limit of detection and the capability to detect cell viability. Perhaps the best strategy for
325 MRSA detection would be to use LAMP based assay for quick screening of clinical samples
326 and then perform multiplex PCR or biochemical assay to re-confirm the presence of MRSA if
327 so desired by the clinician. Such approach will help in saving the precious time lost with
328 processing of negative samples in conventional methods, while reducing the cost too.

329

330 **5. Conclusions**

331 In conclusion, our study highlights significant discordance in outputs of the diagnostic
332 performances and efficiency between three different methods used for MRSA detection in
333 clinical pus isolates. Significant discordance was seen among the diagnostic results of three
334 methods, with LAMP based method detecting highest number of MRSA infections. Within the
335 nucleic acid amplification-based methods, case-wise comparison was made to identify the
336 non-concordant samples. A melt curve analysis (MCA) was used to identify the presence of
337 CoNS for non-concordant samples while other reasons leading to discrepancies are
338 elaborately discussed. The study highlights the robustness and loopholes of different
339 approaches used for MRSA method and the factors which should be considered for the
340 development of an advanced and more specific detection method. One of the best strategies
341 for MRSA detection would be to use LAMP based assay for quick screening of clinical samples
342 and then perform multiplex PCR or biochemical assay to re-confirm the MRSA presence if
343 desired by the clinician.

344

345

346 References

- 347 1. Kluytmans J, Harbarth S. MRSA transmission in the community: emerging from under
348 the radar. *Lancet Infect Dis.* 2019;
- 349 2. Dulon M, Haamann F, Peters C, Schablon A, Nienhaus A. Mrsa prevalence in european
350 healthcare settings: A review. *BMC Infect Dis.* 2011;
- 351 3. Otto M. Community-associated MRSA: What makes them special? *International*
352 *Journal of Medical Microbiology.* 2013.
- 353 4. Pierce R, Lessler J, Popoola VO, Milstone AM. Meticillin-resistant *Staphylococcus*
354 *aureus* (MRSA) acquisition risk in an endemic neonatal intensive care unit with an
355 active surveillance culture and decolonization programme. *J Hosp Infect.*
356 2017;95(1):91–7.
- 357 5. Coughenour C, Stevens V, Stetzenbach LD. An evaluation of methicillin-resistant
358 *Staphylococcus aureus* survival on five environmental surfaces. *Microb drug Resist.*
359 2011;17(3):457–61.
- 360 6. van de Sande-Bruinsma N, Leverstein van Hall MA, Janssen M, Nagtzaam N, Leenders
361 S, de Greeff SC, et al. Impact of livestock-associated MRSA in a hospital setting.
362 *Antimicrob Resist Infect Control.* 2015;
- 363 7. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-
364 resistant *Staphylococcus aureus*: An emerging threat. *Lancet Infectious Diseases.*
365 2005.
- 366 8. Goh ZNL, Chung PY. Letters to the Editor Incidence of methicillin-resistant
367 *Staphylococcus aureus* contamination on mobile phones of medical students Is it
368 necessary to test the sterility of urine prior to outpatient cystoscopy ? *J Hosp Infect.*
369 2019;101(4):482–3.
- 370 9. Bellini D, Koekemoer L, Newman H, Dowson CG. Novel and Improved Crystal
371 Structures of *H. influenzae*, *E. coli* and *P. aeruginosa* Penicillin-Binding Protein 3
372 (PBP3) and *N. gonorrhoeae* PBP2: Toward a Better Understanding of β -Lactam
373 Target-Mediated Resistance. *J Mol Biol.* 2019;
- 374 10. Østergaard C, Møller JK. Subdivision of MRSA CC398 isolates using MALDI-TOF MS.
375 *Int J Med Microbiol.* 2018;
- 376 11. Cadena J, Thinwa J, Walter EA, Frei CR. Risk factors for the development of active
377 methicillin-resistant *Staphylococcus aureus* (MRSA) infection in patients colonized
378 with MRSA at hospital admission. *Am J Infect Control.* 2016;44(12):1617–21.
- 379 12. Kniehl E, Becker A, Forster DH. Bed, bath and beyond: Pitfalls in prompt eradication
380 of methicillin-resistant *Staphylococcus aureus* carrier status in healthcare workers. *J*
381 *Hosp Infect.* 2005;
- 382 13. Silverman SM, Moses JE, Sharpless KB. Reengineering Antibiotics to Combat Bacterial
383 Resistance: Click Chemistry [1,2,3]-Triazole Vancomycin Dimers with Potent Activity
384 against MRSA and VRE. *Chem - A Eur J.* 2017;
- 385 14. Kaur A, Ruhela A, Sharma P, Khariwal H, Seth S, Kumar A, et al. Simultaneous and
386 high sensitive detection of *Salmonella typhi* and *Salmonella paratyphi a* in human
387 clinical blood samples using an affordable and portable device. *Biomed Microdevices.*
388 2019;
- 389 15. Abram TJ, Cherukury H, Ou C-Y, Vu T, Toledano M, Li Y, et al. Rapid bacterial
390 detection and antibiotic susceptibility testing in whole blood using one-step, high

- 391 throughput blood digital PCR. *Lab Chip*. 2020;
- 392 16. Paule SM, Pasquariello AC, Thomson RB, Kaul KL, Peterson LR. Real-time PCR can
393 rapidly detect methicillin-susceptible and methicillin-resistant *Staphylococcus*
394 *aureus* directly from positive blood culture bottles. *Am J Clin Pathol*. 2005;
- 395 17. McElhinney R, Millar C, Scopes E. Comparative evaluation of chromID MRSA agar and
396 Brilliance 2 MRSA agar for detection of MRSA in clinical samples. *Br J Biomed Sci*.
397 2013;
- 398 18. Eigner U, Veldenzer A, Holfelder M. Validation of the FluoroType® MRSA assay for
399 the rapid identification of methicillin-resistant *Staphylococcus aureus* directly from
400 patient material. *J Microbiol Methods*. 2014;
- 401 19. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-
402 mediated isothermal amplification of DNA. *Nucleic Acids Res*. 2000;28(12):E63.
- 403 20. Medalla F, Gu W, Mahon BE, Judd M, Folster J, Griffin PM, et al. Estimated incidence of
404 antimicrobial drug--resistant nontyphoidal *Salmonella* infections, United States,
405 2004--2012. *Emerg Infect Dis*. 2017;23(1):29.
- 406 21. Eriksson E, Aspan A. Comparison of culture, ELISA and PCR techniques for
407 salmonella detection in faecal samples for cattle, pig and poultry. *BMC Vet Res*.
408 2007;3.
- 409 22. Tanner NA, Zhang Y, Evans TC. Visual detection of isothermal nucleic acid
410 amplification using pH-sensitive dyes. *Biotechniques*. 2015;
- 411 23. Tomita N, Mori Y, Kanda H, Notomi T. Loop-mediated isothermal amplification
412 (LAMP) of gene sequences and simple visual detection of products. *Nat Protoc*. 2008;
- 413 24. Tansarli GS, LeBlanc L, Auld DB, Chapin KC. Diagnostic accuracy of pre-surgical
414 *Staphylococcus aureus* PCR assay compared to culture and post-PCR implementation
415 surgical site infection rates. *J Mol Diagnostics [Internet]*. 2020 May [cited 2020 May
416 31];0(0). Available from:
417 <https://linkinghub.elsevier.com/retrieve/pii/S1525157820303275>
- 418 25. Rabaan AA, Bazzi AM. Variation in MRSA identification results from different
419 generations of Xpert MRSA real-time PCR testing kits from nasal swabs. *J Infect*
420 *Public Health*. 2017;
- 421 26. Alipour F, Ahmadi M, Javadi S. Evaluation of different methods to detect methicillin
422 resistance in *Staphylococcus aureus* (MRSA). *J Infect Public Health*. 2014;
- 423 27. Gunderson CG, Holleck JL, Chang JJ, Merchant N, Lin S, Gupta S. Diagnostic accuracy of
424 methicillin-resistant *Staphylococcus aureus* nasal colonization to predict methicillin-
425 resistant *S aureus* soft tissue infections. *Am J Infect Control*. 2016;44(10):1176–7.
- 426 28. Bowers KM, Wren MWD, Shetty NP. Screening for methicillin resistance in
427 *Staphylococcus aureus* and coagulase-negative staphylococci: An evaluation of three
428 selective media and Mastalex-MRSA latex agglutination. *Br J Biomed Sci*. 2003;
- 429 29. CLSI document M47-A. Principles and Procedures for Blood Cultures; Approved
430 Guideline. *Clin Lab Standars Inst*. 2007;
- 431 30. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification (
432 LAMP): principle , features , and future prospects. 2015;53(1):1–5.
- 433 31. Heydari N, Alikhani MY, Tahmasebi H, Asghari B, Arabestani MR. Design of melting
434 curve analysis (MCA) by real-time polymerase chain reaction assay for rapid
435 distinction of staphylococci and antibiotic resistance. *Arch Clin Infect Dis*. 2019;
- 436 32. Lee D, Kim EJ, Kilgore PE, Kim SA, Takahashi H, Ohnishi M, et al. Clinical Evaluation of

- 437 a Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of
438 *Neisseria meningitidis* in Cerebrospinal Fluid. *PLoS One*. 2015;10(4):e0122922.
- 439 33. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The
440 molecular evolution of methicillin-resistant *Staphylococcus aureus*. *Clinical*
441 *Microbiology and Infection*. 2007.
- 442 34. Brukner I, Oughton M, Giannakakis A, Kerzner R, Dascal A. Significantly improved
443 performance of a multitarget assay over a commercial scmec-based assay for
444 methicillin-resistant *Staphylococcus aureus* screening: Applicability for clinical
445 laboratories. *J Mol Diagnostics*. 2013 Sep 1;15(5):577–80.
- 446 35. Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K, Tiensasitorn C, et al. Structural
447 comparison of three types of staphylococcal cassette chromosome *mec* integrated in
448 the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents*
449 *Chemother*. 2001;
- 450 36. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence
451 of methicillin-resistant *Staphylococcus aureus* as a public-health threat. *Lancet*. 2006.
- 452 37. Becker K, Denis O, Roisin S, Mellmann A, Idelevich EA, Knaack D, et al. Detection of
453 *mecA*- and *mecC*-positive methicillin-resistant *Staphylococcus aureus* (MRSA)
454 isolates by the new Xpert MRSA Gen 3 PCR assay. *J Clin Microbiol*. 2016;
- 455 38. Palavecino EL. Rapid methods for detection of MRSA in clinical specimens. *Methods*
456 *Mol Biol*. 2014;
- 457 39. Chan C, Carson L, Smith GC, Morelli A, Lee S. Applied Surface Science Enhancing the
458 antibacterial performance of orthopaedic implant materials by fibre laser surface
459 engineering. *Appl Surf Sci*. 2017;404:67–81.
- 460 40. Peterson LR, Woods CW, Davis TE, Wang ZX, Young SA, Osiecki JC, et al. Performance
461 of the cobas MRSA/SA Test for Simultaneous Detection of Methicillin-Susceptible and
462 Methicillin-Resistant *Staphylococcus aureus* from Nasal Swabs. *Am J Clin Pathol*.
463 2017;
- 464 41. Grmek-Kosnik I, Dermota U, Ribic H, Storman A, Petrovic Z, Zohar-Cretnik T.
465 Evaluation of single vs pooled swab cultures for detecting MRSA colonization. *J Hosp*
466 *Infect*. 2018;98(2):149–54.
- 467 42. Sloane AJ, Pressel DM. Culture Pus, Not Blood: Decreasing Routine Laboratory
468 Testing in Patients With Uncomplicated Skin and Soft Tissue Infections. *Hosp Pediatr*.
469 2016;
- 470 43. Zwemer E, Stephens JR. Things we do for no reason: Blood cultures for
471 uncomplicated skin and soft tissue infections in children. *J Hosp Med*. 2018;
- 472 44. Rudkjøbing VB, Thomsen TR, Xu Y, Melton-Kreft R, Ahmed A, Eickhardt S, et al.
473 Comparing culture and molecular methods for the identification of microorganisms
474 involved in necrotizing soft tissue infections. *BMC Infect Dis*. 2016;
- 475 45. Yang H, Ma X, Zhang X, Wang Y, Zhang W. Development and evaluation of a loop-
476 mediated isothermal amplification assay for the rapid detection of *Staphylococcus*
477 *aureus* in food. *Eur Food Res Technol*. 2011;
- 478 46. Kahánková J, Pantůček R, Goerke C, Růžičková V, Holochová P, Doškař J. Multilocus
479 PCR typing strategy for differentiation of *Staphylococcus aureus* siphoviruses
480 reflecting their modular genome structure. *Environ Microbiol*. 2010;
- 481 47. Stürenburg E. Rapid detection of methicillin-resistant *Staphylococcus aureus* directly
482 from clinical samples: methods, effectiveness and cost considerations. German

483 medical science : GMS e-journal. 2009.
484 48. French GL. Methods for screening for methicillin-resistant Staphylococcus aureus
485 carriage. Clinical Microbiology and Infection. 2009.
486
487

488

Table 1. Sequence of primers used for LAMP based amplification of *mecA* gene.

Primer name	Primer sequence
F3	5'-TGATGCTAAAGTTCAAAAGAGT-3'
B3	5'-GTAATCTGGAAGTTGTTGAGC-3'
FIP	5'-TGAAGGTGTGCTTACAAGTGCTAAT-CAACATGAAAAATGATTATGGCTC-3'
BIP	5'-TGACGTCTATCCATTTATGTATGGC-AGGTTCTTTTTTATCTTCGGTTA-3'

489

490 Table 2. Primer sequence used for Melt Curve Analysis (MCA) based distinction between MRSA and CoNS.
491

Primer name	Primer sequence	Target gene	Presence of gene in organism	MRSA confirmation	CoNS confirmation
F-16S	5'-ACTTCGGGAAACCGGAGC-3'	16S rRNA	Gene specific to <i>Staphylococcus</i> (MRSA, CoNS etc.)	Amplification of all three targets	Amplification of only 16S rRNA and <i>mecA</i> gene but not ITS
B-16S	5'-ACCGTGTCTCAGTTCCAG-3'				
F-ITS	5'-GTTAGAGCGCACGCCTGATA-3'	ITS	Gene specific to <i>S. aureus</i> but not does not confirm methicillin resistance	Amplification of all three targets	Amplification of only 16S rRNA and <i>mecA</i> gene but not ITS
B-ITS	5'-AATGGTGGAGACTAGCGGGA-3'				
F- <i>mecA</i>	5'-TGATGCTAAAGTTCAAAAGAGT-3'	<i>mecA</i> gene	Gene specific to both MRSA and CoNS	Amplification of all three targets	Amplification of only 16S rRNA and <i>mecA</i> gene but not ITS
B- <i>mecA</i>	5'-GTAATCTGGAAGTTGTTGAGC-3'				

492

493 Table 3. Culture results of the 225 clinical pus samples tested for MRSA presence using three different diagnostic methods.
 494 Statistical Analysis of diagnostic performance of the methods is included in the table.
 495

Diagnostic Method	Detection, n (%)		Observation			Sensitivity* (%)	Negative Predictive Value (NPV)** (%)
	Positive	Negative	Positive in at least one method	Positive in all three methods	Negative in all three methods		
Culture method	30	187				24.6	50.8
qPCR	67	150	122	13	95	54.9	63.3
LAMP assay	104	113				85.2	84.1

496 n: number of samples; NPV: negative predictive value; LAMP: loop-mediated isothermal amplification;
 497 qPCR: quantitative polymerase chain reaction. Formulas used for statistical calculations are included in the supplementary section.
 498 * Sensitivity = Positive in the corresponding method/Positive in atleast one of the methods
 499 **NPV= Negative in all the methods/Negative in the corresponding method
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513

514
515
516

Table 4a. Estimating the discordance between the MRSA detection results through three different approaches. Diagnostic output of 217 clinical samples was categorized in 8 groups.

Concordance	LAMP assay	qPCR	Culture method	n (%)
^{\$} Concordant	+	+	+	13
Discordant	+	+	-	38
Discordant	+	-	+	14
Discordant	-	+	+	1
Discordant	-	-	+	2
Discordant	-	+	-	15
Discordant	+	-	-	39
[*] Concordant	-	-	-	95
Total				217
% Discordance = [(Total - Concordant)/Total]*100				50.2

517

n: number of samples; NPV: negative predictive value; LAMP: loop-mediated isothermal amplification;

518

qPCR: quantitative polymerase chain reaction

519

*True negative => Negative in all methods = 95

520

^{\$}True positive => Positive in all methods = 13

521

522

523

524

525

526
527

Table 4b. Pairwise comparison and estimation of discordance in MRSA detection results using three different methods.

Concordance	Findings	Culture vs. qPCR n (%)	Culture vs. LAMP n (%)	qPCR vs. LAMP n (%)
Concordant	(+), (+)	14	27	51
Concordant	(-), (-)	134	110	97
Discordant	(+), (-)	16	3	16
Discordant	(-), (+)	53	77	53
Total		217	217	217
% Discordance = [(Total – Concordant)/Total]*100		31.8	36.9	31.8

528
529
530
531

n: number of samples; LAMP: loop-mediated isothermal amplification; qPCR: quantitative polymerase chain reaction

532

Table 5. Summarized results for melt curve analysis for 69 discordant samples.

Organism	No of samples (%)	Sample ID
CoNS	17 (24.3)	US322, AK491, CD566, SK733, RA976, SI989, AP755, SU370, SK870, MK889, IA128, N368, V882, AK285, SI292, SD269, NB291
MRSA	52 (75.7)	RO073, NN999, DP141, PC923*, PO083, RC152, RN055, SD079, ND430, LK633, WK892, SK151, VS270, SD829, NK116, JT336, KD055, NM031, VJ269, SK515, SB228, G303, AK285, PD464, CS513, JK931, AY258, KP056, AR905, UD757, PD171, NJ590, DS969, BP368, DS858, RS224, D291, AK865, SC940, PK448, SD831, H418, MD272, MD272, JM305, RK576, SS115, VB411, DG170, BS544, SR661, PD884
Total	70	

533

534

Table 6. MRSA detection results and statistical analysis for LAMP and qPCR method after considering CoNS contamination.

Nucleic acid based Diagnostic Methods	From melt curve analysis				Sensitivity (%)	Specificity (%)	Positive predictive value (PPV) (%)	Negative predictive value (NPV) (%)
	True Positive	True Negative	False positive*	False negative**				
qPCR	64	109	3	41	61.0	97.3	95.5	72.7
LAMP assay	90	98	14	15	85.7	87.5	86.5	86.7

535

n: number of samples; TP: true positive; FP: false positive; TN: true negative; FN: false negative; PPV: positive predictive value; NPV: negative predictive value; LAMP: loop-mediated isothermal amplification; qPCR: quantitative polymerase chain reaction.

536

*False Positive – Samples detected as MRSA positive but found contaminated with CoNS through MCA.

537

**False negative – (Total positive in the corresponding diagnostic method – True positive)

538

539






Figure 1. Schematic showing workflow for the comparative study.


541
542
543



544 Figure 2. (a) Case wise comparison of diagnostic efficacy different molecular diagnostic
 545 methods used for MRSA detection. (b) Comparative performance of different diagnostic
 546 methods on 54 Clinical pus samples (6 samples showed negative results in all three methods
 547 while 48 clinical pus isolates recorded non-concordant results).
 548
 549
 550



551
 552
 553 Figure 3. Comparative performance of different diagnostic methods on 122 positive clinical
 554 pus samples out of 217 total samples (95 samples showed negative results by all three
 555 methods and hence excluded from the diagram).
 556



557
558
559
560

Figure 4. Melt curve analysis (MCA) for identifying CoNS contamination in the discordant samples. (a) to (c) Melt curves for three control samples and (d) to (f) three representative samples (JT336, NK116 and CD566)